Eye exposure to organophosphate (OP) irreversible acetylcholinesterase inhibitors, results in long-term miosis and impaired visual function. The aim of this study was to find an anticholinergic antidote, which would counteract miosis and visual impairment induced by the nerve agents sarin and VX with minimal untoward side-effects. Rat pupil width and light reflex were evaluated from 15 min up to 2 weeks following topical OP exposure with or without topical ocular treatment of atropine or homatropine or with a combined intramuscular treatment of trimedoxime (TMB-4) and atropine (TA). Visual function following insult and treatment was assessed using a cued Morris water maze task. Topical VX exposure showed a dose-dependent miosis with a significant reduction in visual function similar to the effect seen following sarin exposure. Homatropine (2%; w/v) and atropine (0.1%; w/v) treatment ameliorated both sarin and VX-induced miosis and the resulting visual impairment. TA treatment was sufficient in ameliorating the sarin-induced ocular impairment while an additional ocular treatment with either 0.1% atropine or 2% homatropine was necessary following VX exposure. To conclude the use of 0.1% atropine or 2% homatropine was beneficial in ameliorating the ocular insult following VX or sarin ocular exposure and thus should be considered as universal treatments against this intoxication. The findings also emphasize the necessity of additional ocular treatment to the systemic treatment in visually impaired casualties following VX exposure.
The anticholinesterase compounds sarin (isopropyl methyl phosphonofluridate) and VX (O-ethyl-S-[2 (diisopropylamino) ethyl] methylphosphonothioate) are extremely toxic organophosphate (OP) nerve agent. Sarin has been used in the past as a warfare agent in both terrorist attacks in Japan (Yanagisawa et al., 2006) and lately in the civil war in Syria (Dolgin, 2013; Rosman et al., 2014) while VX has been used up to now in local events in Japan (Schmid, 1999) .
At low doses, these nerve agents may be used to induce visual incapacitation. Topical OP ocular exposure leads to a reduction in cholinesterase (ChE) activity in the iris and ciliary muscle (Dabisch et al., 2005b; Lund-Karlsen and Fonnum, 1976) with subsequent elevation of acetylcholine (Mattio et al., 1984) . This cholinergic over-stimulation action on the pupillary sphincter results in a marked miosis (a reduction of at least 50% of pupil diameter) with dim vision, decrease in spatial visual ability and a decline in adapting to illumination changes due to desensitization of pupillary muscarinic receptors (Dabisch et al., 2008; Genovese et al., 2008; Lund-Karlsen and Fonnum, 1976; Takayanagi et al., 1993) . In addition, the cholinergic overstimulation action induces ciliary muscle spasm, which may lead to blurred vision and myopia (Cannard, 2006; Nohara and Segawa, 1996; Rengstorff, 1985; Smith and Smith, 1980; Yanagisawa et al., 2006) .
Very mild casualties suffering only from OP-induced ocular insult, may benefit from topical (Ohbu et al., 1997; Okudera, 2002) rather than systemic anticholinergic treatment (Ohbu et al., 1997; Yanagisawa et al., 2006) since systemic treatment may show general side effects with no ocular benefit (Hurst et al., 2007) .
We have previously shown that topical treatment with tropicamide may partially ameliorate the sarin-induced ocular insult (Gore et al., 2012) , while a combined topical treatment of tropicamide with oximes (Gore et al., 2014) or a combined intramuscular (i.m.) treatment of atropine with oximes (Gore et al., 2015) ameliorated the ocular deficit following ocular sarin exposure. Other treatments such as the long-term anticholinergic eye drop atropine (1%), induced long-term mydriasis in sarin exposed eyes (Gore et al., 2012) . The anti-cholinergic drug cyclopentolate, has even been shown to worsen visual acuity and visual function following sarin ocular exposure (Gore et al., 2012; Holstege et al., 1997; Sidell and Borak, 1992) . Since ocular sarin exposure may result in prolonged miosis (several days to several weeks) (Munro, 1994; Rengstorff, 1994; Yanagisawa et al., 2006) , repeated treatments may be required in all ocular symptom presenting casualties (Ohbu et al., 1997) . VX exposure may show a much longer effect than sarin as it is stored in various tissues and may be slowly released over time with continuous or delayed clinical effects (Hamilton et al., 2004b) .
The physiological mechanism of pupil size is controlled both by the sympathetic and parasympathetic branches of the autonomic nervous system. Stimulation of the a-adrenergic receptors located on the radial muscles of the iris will result in dilation of the pupil (Yu, 2002 (Yu, , 2003 , while stimulation of the muscarinic receptors of the pupillary sphincter will result in constriction of the pupil (Furuta et al., 1998; Smith et al., 1996) . A single ocular sarin exposure, is not known to induce muscarinic desensitization (Dabisch et al., 2007b; Gore et al., 2012) while repeated exposure to sarin (Dabisch et al., 2007b) may result in desensitization of muscarinic receptors and reduced miotic response (Dabisch et al., 2005b; Soli et al., 1980; Tandon et al., 1994; Tang et al., 1999) . Due to the low clearance of VX from the targeted tissue, exposure to this compound may show a similar effect of the repeated exposure to sarin an issue, which will be evaluated in this work.
Taking into account the different properties of sarin and VX, seeking to minimize repeated treatments, and reducing side effects of mydriasis and cycloplegia in cases of misuse (Bartlett et al., 2008) , we sought to determine the feasibility of using lower doses of long-term anticholinergic drugs as a universal treatment in counteracting ocular symptoms following OP exposure. Successful treatment will be determined by the beneficial outcome of maintaining a functional pupil width and normal visual acuity over time following ocular exposure of sarin or VX.
In mild casualties with additional symptoms such as lacrimation, increased salivation, rhinorrhea, tightness in the chest, sweating, nausea, vomiting, and abdominal cramps, systemic (i.m.) treatment of atropine and oximes will be used (Holstege et al., 1997; Sidell et al., 1997; Weissman and Raveh, 2011) . Atropine treatment (i.m.) alone showed no beneficial role in ameliorating ocular symptoms in humans, (Grob and Harvey, 1958; Kay and Morrison, 1988; Ohbu et al., 1997; Yanagisawa et al., 2006) unless administered at very high doses (Cannard, 2006) . The combined treatment of atropine with oximes (i.m.) has been shown to widen pupils in rats and rabbits following sarin exposure (Gore et al., 2014; Macic et al., 1990) and reactivate inhibited ChE (Lund-Karlsen and Fonnum, 1976) . Thus, another goal of this study was to determine the potential beneficial effect of the combined trimedoxime (TMB-4) and atropine (TA) treatment, used in mild or severe casualties against VX induced ocular insult and determine if additional topical treatments would be essential. The treatments used in this study were evaluated for their role in ameliorating the sarin and VXinduced ocular impairment in the rat model by assessing pupil width, iris contraction ability and visual function.
MATERIALS AND METHODS

Chemicals
Isopropyl methylphosphono-fluoridate (sarin) and O-ethyl S-(2 diisopropylaminoethyl) methylphosphonothiolate (VX) were synthesized by the department of Organic Chemistry (Israel Institute for Biological Research [IIBR] ) and its purity of >95% was determined by quantitative NMR. Sarin and VX stock solution of 30 or 10 mg/ml (respectively) in propylene glycol (PG) were prepared and stored at À20 C. Sarin and VX solutions in saline were freshly prepared before each experiment. Tropicamide 0.5% (w/v) and Atropine 1% (w/v) were purchased as commercial eye drops: MydramideV R 0.5% (w/v) (Benzeneacetamide, N-ethyl-a-(hydroxymethyl)-N-(4-pyridinylmethyl)-) and Atrospan V R 1% (w/v) (Bis[(1R,3r,5S)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl (2RS)-3-hydroxy-2-phenylpropanoate] sulfate monohydrate) respectively from Fischer Pharmaceutical Laboratories, Tel-Aviv, Israel. Saline was purchased as a commercial product from Teva Medical, Ashdod, Israel. HI-6 [1-(2-hydroxyiminomethylpyridinium)-3-(4-karbamoylpyridinium)-2-oxapropan dimethanesulfonate], was purchased from Chemprotect, Prague, Czech Republic. TMB-4 (1, 3-bis [4-hydroxyiminomethylpyridinium]-propanedichloride), PG, benzalkonium chloride (alkylbenzyldimethylammonium chloride) and Homatropine (DL-endo-a-Hydroxybenzeneacetic acid 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ester hydrobromide) were purchased from Sigma, Rehovot, Israel.
Oximes, PG, homatropine, and atropine solutions were prepared in saline before each experiment. Solutions for topical use were prepared with the ophthalmic preservative benzalkonium chloride 0.02% (w/v) (Bartlett et al., 2008; Sweetman, 2002) .
The drugs and chemicals used in this study conform to the British Journal of Pharmacology's Guide to Receptors and Channels (Alexander et al., 2011) .
Animals
Male Long-Evans rats (200-300 g) were purchased from CharlesRiver, Boston, Massachusetts, USA. Animals were housed in ambient conditions of 3 animals per cage, temperaturecontrolled environment at 21 C 6 2 C and 40%-70% humidity, 12-h light/dark cycle (lights on at 6 AM). Rats were provided with Altromin 1324 pellets (Altromin, Lage, Germany) and tap water ad libitum during the study and were maintained in accordance with the principles enunciated in the Guide for the Care and Use of Laboratory Animals, Eighth Edition, National Academy Press, Washington, District of Columbia, 2010. Experimental procedure began at least 1 week following acclimatization. The experimental protocols were approved by the IIBR committee for animal care and use, and were designed to prevent or minimize any unnecessary pain and stress. Animals were euthanized by carbon dioxide asphyxiation 24 h following the experimental procedure. This study is reported in accordance with ARRIVE guidelines for reporting experiments involving animals (Kilkeny et al., 2010; McGrath et al., 2010) .
Infrared Pupil Photography
Pupil diameter was digitally photographed and measured by an Infrared (IR)-based system, adapted from the "ViewPoint Eye Tracker" from humans to small animals. It comprised of 3 components: IR spot light, IR video camera and "Eye Tracker" software (ViewPoint Eye Tracker, PC-60, Arrington Research Inc., 2002) . The measurements were based on retina reflection of IR light (Hulet et al., 2006) , which unlike white light has no effect on pupil width (Soli et al., 1980) and causes no discomfort and movement of the animal (Dabisch et al., 2007b) . The optical system supplied a video signal of the pupil in suitable magnification and with best contrast so that the pupil was darker than the surrounding. The image was transferred, displayed and analyzed by the "Eye Tracker" software. The pupil was identified in the visual field, designated according to the contrast distinction compared with the surroundings. The pupil width was indicated by a yellow spherical mark and determined in pixel units. Measurements were presented as a ratio of pupil width to the window length of the eye display, which was constant to correct for variability between measurements due to variations in the distance from the camera to the eye.
Sarin and VX Exposure, Treatment Protocols, and Ocular Measurements The left eye of each rat (n ¼ 12 for each exposure and treatment group) was digitally photographed before (baseline), then following exposure, and after treatment to determine the degree of pupil width changes produced by the nerve agents with and without the treatments. Pupil width measurements of each rat at all-time points were recorded relative to their own baseline and images were obtained after the animals were allowed to adjust to controlled low-light conditions (2 lux) for 15 min.
Hand restrained animals were topically exposed to 0.007, 0.025, 0.04, 0.1, 0.5, and 1 lg VX or 1 lg sarin in the left eye in a fume hood, where animals remained for at least 10 min after exposure to prevent environmental contamination.
Exposure of 1 eye with 1 mg sarin was carried out based on previous results, showing pinpoint pupils and a reduction in visual performance with no systemic intoxication or change in peripheral blood ChE activity following this exposure (Gore et al., 2012) . Pupil width was measured 15 min after sarin and VX exposure and continued for up to a maximum of 14 d (days). Fifteen minutes following a single topical exposure to sarin, VX or 0.66% (w/v) PG, pupil width measurements were performed (n ¼ 12 for each treatment group). For the experiments determining the role of the sympathetic activity of the iris at the late time points following VX exposure, 72 h following exposure, pupil diameter was evaluated followed by a-adrenergic receptor antagonist phentolamine (5 mg/kg i.m.) treatment and 30 min later the pupil's diameters were re-evaluated. The dose of phentolamine used, has been previously shown to block a-adrenergic receptor-mediated activity in the heart (Barres et al., 2001) .
In experiments evaluating treatments, 20 min after exposure to 1 lg VX or sarin, animals were treated with 1 or 2 drops of either 0.5% tropicamide (w/v) with or without 2.5% HI-6 (w/v), atropine (0.025, 0.05, 0.1, 0.2, 0.25, and 1%), homatropine (2, 5% or 10%), or i.m. treatment of TA (7.5 mg/kg TMB-4 with 0.5 mg/kg atropine) followed by an additional topical treatment of atropine 0.1% (w/v) or homatropine 2% (w/v). Control animals exposed to the diluent PG were treated with the same treatments as the OP exposed groups in order to evaluate possible side effects. All treatments assessed in this study on pupil changes are summarized in Table 1 . Effect of treatment on pupil diameters was determined 10 min following treatment (30 min after VX or sarin exposure) and at 1, 2, 4, 6, 8, 24, 32, 48, 72, 96 , and 168 h following exposure. Volume of all eye drops used in this study was 5 ml/eye and 150 ml/300g animal for the i.m. treatments. Light reflex: Alterations in the ability of the iris to contract in response to light, provided a sensitive method to determine the functional state of muscarinic receptors of the papillary sphincter (Dabisch et al., 2007b) . Evaluation of pupil response in the left eye was measured at 1, 4, 24, 48, 72, 96, 144 , and 168 following exposure and in some experiments continued for up to 14 days (336 h) (Gore et al., 2012) . Briefly, the exposed left eye was illuminated with 350 lux for 2-3 s and pupil diameter was immediately determined. Light reflex is presented as the % of pupil width constriction change of the prereflex level. The normal physiological range of light reflex change in LongEvans rats was determined following examination of 36 naïve eyes to be 35-57% with a mean 6 SD of 46 6 11 (Gore et al., 2015) .
Cued Morris Water Maze Task
Visual function was assessed by the use of cued morris water maze (MWM) task, in which target location is marked by a single visible cue (Brandeis et al., 1989; Hamilton et al., 2004a; Morris, 1984) . Animal performance in the maze was monitored by an overhead tracking video camera connected to an image analyzer (HVS Image, Hampton, UK) and analyzed by the water maze software HVS WATER 2020 (Gore et al., 2012) . Briefly, rats were evaluated in the water maze during a 1 daily session of 4 trials (4 trials per block, two blocks). In each block rats departed from 1 of 4 equally spaced starting points (in each quadrant) and the target platform was located at 1 out of 4 randomly selected sites. The rat was expected to find and swim to the platform by identifying the cue (green rod) that signaled the platform location. Spatial learning was minimized by a curtain surrounding the maze. Escape latency (time to reach the platform), path length and swimming speed were recorded in each trial.
Procedure
Both eyes of rats (n ¼ 12) were exposed topically to 1 lg VX or 0.66% (w/v) PG (control) at a volume of 5 ll per eye. Ten minutes following exposure, rats were taken out of the fume hood and 5 min later pupil width was determined, followed by performance of the visual task at 35 min, 4, 24, and 48 h. Animals used for efficacy evaluation of anticholinergic drugs following 1 lg VX or sarin were treated approximately 20 min following topical exposure. A second pupil width examination was done 35 min after exposure (approximately 15 min following treatment administration) and just before the visual performance test was done.
The treatments examined were 0.1% atropine and 2% homatropine and the visual task was performed at the indicated time points as specified in Table 2 . Homatropine 2% Blood ChE Blood (40 ml) was first collected from the tail vein of 6 animals to establish ChE activity baseline. Following topical 1 eye exposure to 0.01, 0.04, 0.1, 0.5, 1, or 1 mg VX, blood was collected from the tail vein at 1.5 and 24 h or 0. 5, 4, 24, 48, 72, 96 h, 7, 11, and 16 days following 2 eye exposure to 1 mg VX. Samples were analyzed for ChE activity according to the method of Johnson and Russell (Johnson and Russell, 1975; Russell et al., 1985) . Results are expressed as percentage of baseline ([post /basal CPM Â 100]/protein) and presented as mean 6 SEM.
Data Analysis
Baseline pupil width was determined a day prior to exposure (mean of 2 independent measurements). Pupil width at different time points following exposure and various treatments were calculated as percent of baseline. Light reflex was calculated as percent of pupil width change relative to pre-reflex level. Results were analyzed separately for each of the measurements by a mixed ANOVA model with the type of exposure (sarin/PG/VX) and treatment (Table 1) as between subject factors, and time postexposure as within subject factor. Specific comparisons were performed using an analysis of simple main effects for interactions, with a Bonferroni adjustment for multiple comparisons. Miosis ED 50 following VX exposure was calculated by using probit analysis and miosis was defined as a reduction of at least 50% in pupil diameter. Visual performance scores (escape latency, path length, and swimming speed) were analyzed by a 3-way MANOVA, with 1 repeated variable (blocks) and 2 nonrepeated variables (group and treatment). Specific comparisons were performed as above. All scores are reported as mean 6 SEM and values of p < .05 were considered statistically significant for all tests.
RESULTS
Effect of Topical VX Exposure on Pupil Width
The effect of various doses of topical VX exposure on pupil constriction is summarized in Figure 1A . As can be seen, pupil diameter was dose-dependently reduced starting with the lowest dose tested (0.007 mg), and as exposure dose increased a more severe and rapid pupil constriction was observed (p < .05-.001) followed by slower recovery rates. At the higher doses of 0.5 or 1 mg VX a slow recovery was observed only after 24-32 h, followed by a state of mydriasis (over-widening) at 48 h and returning to baseline only a week later (at 168 h). Light reflex assay was used to determine possible physiological deficit of the iris constriction ability following VX exposure ( Figure 1B ). An intact light reflex was seen in the control group exposed to PG and in the groups exposed to 0.007-0.1 mg of VX. Eyes exposed to the higher doses of 0.5 and 1 mg VX showed an impairment in iris constriction ability for up to 96 h (p < .01-.001). The miosis threshold values ( Figure 1C ) from 15 min up to 24 h post VX, were 0.02-0.09 lg demonstrating the potency of this compound as a pupil constrictor. The mydriatic response observed at 48-144 h following exposure to the higher doses of 0.5 and 1 mg VX was unexpected. In order to determine the possible involvement of the sympathetic activity in this effect, rats were treated with the a-adrenergic antagonist phentolamine 72 h postexposure. Control eyes, treated with only PG, were unaffected by this treatment while the mydriatic response observed 72 h post VX exposure was eliminated following phentolamine treatment ( Figure 1D ).
Whole body exposure incorporates multiple routes of administration. Exposure of 1 eye to low doses of 0.5 or 1 mg VX was sufficient to induce blood ChE inhibition of 50% and 80%, respectively, 1.5 h following exposure with a gradual recovery at 24 h postexposure (Supplementary Material 1A) . An example of the gradual ChE recovery over 16 days following single VX exposure of 1mg in both eyes is presented in Supplementary Material 1B.
Visual Function Following Ocular VX Exposure Visual function was evaluated based on performance of the cued MWM task at various time points following both eye exposure to 1 lg VX. For all following experiments evaluating the insult effect and treatment benefit, the more severe insult using 1 mg was used. A significant increase in escape latency ( Figure  2A ; p < .01-.001) and path length ( Figure 2B ; p < .01-.001) was seen in the VX exposed compared with the PG exposed group animals for up to 24 h postexposure, indicating an impaired visual function. This functional impairment was associated with an increase in miosis seen in these animal for up to 24 h postexposure compared with same time controls, followed by mydriasis at 48 h ( Figure 2D ; * ,# p < .001) . No significant differences between the groups in the swimming speed (motor measurement) were observed ( Figure 2C ).
Treatments Against VX-Induced Miosis
In the past, we have shown that i.m. treatment with TA or topical treatment, which consists of 2 drops of tropicamide or 1 drop tropicamide with an oxime were very beneficial in ameliorating the sarin-induced miosis. In order to determine if these treatments may serve as a universal treatment they were evaluated. Eyes exposed to 1 mg VX showed a rapid pupil constriction. Treatment with atropine with TMB-4 (i.m.) or tropicamide (topical) with or without HI-6 (i.m.) resulted in a rapid, shortterm pupil widening, constricting back to pinpoint at 2-4 h posttreatment ( Figure 3A ). In addition, these treatments were unable to prevent the VX-induced mydriasis, which was observed 48 h following exposure or to shorten its time span. These treatments also failed to ameliorate the iris constriction deficit in response to light ( Figure 3B ).
Effect of topical atropine treatment on VX-induced miosis
Since treatments against sarin-induced ocular insult were not beneficial against the VX-induced ocular insult (Figs. 3A and B) , we next evaluated 2 topical drugs, which may potentially serve as a universal treatment. The first was atropine and the second homatropine. Atropine topical treatment following VX exposure presented a dose dependent response of pupil widening ( Figure 4A ). Treatment with the higher dose of 1% atropine was disruptive: it induced a short-term mydriasis of up to 4 h following 1 mg VX exposure, preserving a normal pupil width from 6 to 48 h followed by mydriasis, which continued up to 2 weeks (p < .05-.001). The nonexposed control group treated with 1% atropine presented mydriasis for up to 2 weeks, similar to that seen in humans. The low dose of 0.025% atropine was ineffective as it showed a weak response in pupil widening with no effect on preventing the late mydriatic response similar to the VX-exposed nontreated group. The low dose of 0.1% atropine induced a relatively short-term mydriasis of 24 h in nonexposed eyes and a moderate widening of approximately 50% from 4 to 36 h post VX exposure returning to baseline at 48 h and thus preventing the late VX-induced mydriatic response. All atropine doses evaluated (except for the 0.025%) were beneficial in ameliorating the iris constriction deficit ( Figure 4B ). The control group treated with 1% atropine showed a reduction in iris constriction ability up to 48 h, while the control group treated with 0.1% atropine presented a reduction in this ability only at the first hour following treatment ( Figure 4B ). Because 0.1% atropine treatment induces a relatively short-term mydriasis in control eyes representing the expected side effect in case of misuse, this treatment was examined as a repeated treatment following ocular VX exposure. Twenty minutes following ocular exposure of 1 mg VX, eyes were treated with 0.1% atropine. As shown, pupil widening was induced and remained above the 50% pupil width for up to 4 h ( Figure 5A ). Six hours postexposure, this treatment was no longer effective as pupil width dropped under the 50% pupil width (defined as miosis). At this time point an additional treatment of 0.1% atropine was applied inducing a rapid pupil widening, which preserved pupil width above 50%, preventing the mydriasis observed at 48-72 h. This consecutive treatment also ameliorated the pupillary light reflex deficit ( Figure 5B ).
Effect of topical homatropine treatment on VX-induced miosis
Eyes exposed to 1 mg VX were treated with various doses of homatropine showing a dose response ( Figure 6A ). All doses used widened pupils above 50% of pupil width preventing the late response of mydiriasis. Control animals treated with 2% homatropine presented a relatively short-term mydriasis ( Figure 6A ) similar to the mydriasis induced by 0.1% atropine.
All homatropine doses evaluated here were beneficial in ameliorating the iris constriction deficit ( Figure 6B ). The control group treated with 2% homatropine showed a reduction in iris constriction ability only at the first hour following treatment ( Figure 6B ) similar to the response observed following 0.1% atropine treatment.
Effect of topical atropine treatment on sarin-induced miosis
Since we are seeking a universal treatment against VX and sarininduced ocular insult and because treatments, which showed to be beneficial against sarin, were not efficient against VX, we next evaluated the efficacy of the anticholinergic drugs evaluated above against sarin ocular exposure. Eyes exposed to 1 mg sarin were treated with various atropine doses presenting a dose response of pupil widening ( Figure 7A ). The dose of 0.1% atropine, which showed a relatively short-term mydriasis in the control group counteracted the effect of sarin over time and at 1 h following exposure pupils returned to normal and remained so for the length of the testing period (1 week) ( Figure 7A ). All atropine treatments were also effective in ameliorating the light reflex deficit, except the lowest dose tested of 0.05% at the first hour ( Figure 7B ).
Effect of topical homatropine treatment on sarin-induced miosis
We next evaluated the efficacy of homatropine in ameliorating the sarin-induce insult. Sarin-exposed eyes were treated with various doses of homatropine presenting a dose response of pupil widening ( Figure 8A ). Homatropine 1% presented a weak response while 5% and 10% induced mydriasis. Treatment with 2% homatropine showed a gradual pupil widening, returning to baseline level at 1 h following exposure ( Figure 8A ). All homatropine doses used, ameliorated the sarin-induced light reflex impairment ( Figure 8B ).
Evaluation of combined topical and i.m. treatment against VXinduced miosis
Since many OP casualties will be treated on-site with automatic TA injectors (atropine and an oxime) and since this treatment was shown to be beneficial in ameliorating sarin and partially also against VX-induced ocular insult, we next evaluated the benefit of adding a topical treatment in case of VX ocular exposure. Eyes exposed to VX were treated initially with TA. Four hours later pupils were back to miotic state, and at this stage they were treated with 0.1% atropine or 2% homatropine (Figue 9A). Both treatments showed a beneficial role in pupil widening preventing the delayed mydriatic response ( Figure 9A ). These continuous treatments were also effective in ameliorating the light reflex deficit ( Figure 9B ).
Visual function assessment following ocular VX exposure and anticholinergic treatments
In the performance of the cued water maze task, all anticholinergic treated nonexposed control animals had no effect on escape latency or path length parameters compared with the saline treated control animals (Figs. 10A and B) . Treatment with either 0.1% atropine or 2% homatropine against 1 lg VX exposure abolished the impairment in escape latency and path length parameters in both blocks of trials (p < .001; Figure 10 ) indicating improved visual function by these treatments. No significant differences in the swimming speed were observed between these exposed groups ( Figure  10C ). Visual function assessment following ocular sarin exposure and anticholinergic treatments In the performance of the cued water maze task, all anticholinergic treated nonexposed control animals had no effect on escape latency and path length (Figs. 11A and B) . Treatment with either 0.1% atropine or 2% homatropine against 1 lg sarin exposure, abolished the impairment in escape latency and path length, except in the first block following homatropine treatment, which showed a slight delayed response (p < .001; Figs. 11A and B) indicating improved visual function by these treatments. No significant differences in the swimming speed were observed ( Figure 11C ).
DISCUSSION
The aim of this study was to seek a universal treatment against OP-induced miosis and the associated visual impairment. In real life scenario, ocular exposure is expected to affect most victims, even if only low doses are dispersed. Since at time of exposure the toxic agent will most likely be unidentified, therefore, a universal treatment is essential.
Topical treatments such as tropicamide, oximes, or i.m. atropine with TMB-4 treatment that have been show in the past to be beneficial in counteracting the sarin-induced ocular impairment and have shown a rapid and stable effect (Gore et al., 2012 (Gore et al., , 2015 , failed to do so against VX-induced ocular impairment (Figure 3) . Their effects following VX exposure were rapid, but short-lived. Taken together with the data showing a long-term effect of VX on pupil diameter (Figure 1 ) and on visual function (Figure 2 ) this may indicate that VX is accumulated in the target tissue and slowly released and/or eliminated over time. Previous results suggested slow release of VX over days from subcutaneous depot, which results in the slow elimination of the VX (Van der Schans et al., 2003) and the re-phosphorylation of reactivated ChE (Macic et al., 1990) . The modest reactivity of VX hydrolysis and binding to carboxylesterases further indicate that this agent is more persistent in vivo compared with sarin, parameters which may affect the treatment following VX intoxications (Reiter et al., 2014; Van der Schans et al., 2003) as shown in this study.
Another effect that seems to be related to the persistency of VX is the delayed development of mydriasis induced by high doses of VX (0.5 and 1 mg) and not observed following ocular sarin exposure (Gore et al., 2012) .
The mechanisms responsible for the delayed mydriasis effect may be due to VX-induced muscarinic desensitization, as previous data suggested that repeated, but not acute exposure to sarin induces such desensitization (Dabisch et al., 2007b) . The imbalance between the VX-desensitized parasympathetic cholinergic system, and the unaffected sympathetic noradrenergic Figure 5 . Evaluation of continues 0.1% atropine topical treatment on pupil alterations following topical VX exposure. A, Eyes were topically exposed to1 lg VX and 20 min later were treated topically with 0.1% atropine. An additional treatment was administered 6 h postexposure following pupil constriction to below 50% of pupil width. Pupil width (relative to pre-exposure baseline of the same animal) and B, Light reflex: pupil width change determined post, relative to preillumination with 350 lux for 2-3 s, were determined. Intact light reflex range is indicated by the dotted horizontal lines (n ¼ 12/group), *p < .001 (ANOVA) compared with other groups at the same time point (pupil width), *compared with other groups with no asterisk at the same time point (light reflex). system (Dabisch et al., 2005a) both controlling pupil size (Yu, 2002 (Yu, , 2003 , result in mydriasis. This hypothesis is further supported by the results showing that pretreatment with the a-adrenergic antagonist, phentolamine, reduced the delayed mydriatic effect following VX exposure ( Figure 1D ). Treatment with anti-muscarinic drugs could also prevent the late mydriasis, probably by preventing desensitization of the muscarinic receptors. Indeed, 0.05% atropine or 2% homatropine (Figs. 4 and 6, respectively) were effective in attenuating this effect, although neither i.m atropine with TMB-4 nor topical tropicamide were effective probably because of their low permeability to the eye or due to the low potency, respectively (Figure 3) .
Since treatments, which were found to be beneficial against sarin-induced ocular insult were unable to ameliorate the VXinduced ocular insult, more potent and long-term drugs were evaluated in this study. The delicate balance between the beneficial anti-muscarinic effects and between inducing long-term mydriatic side effects is of continually concern. In this model the more severe insult following 1mg exposure was used. As known from the literature, treatment with 1% atropine may induce a long-term mydriasis in humans for up to approximately 2 weeks (Marron, 1940) . Similar results were observed here in the rat model showing also a reduction in light reflex ability up to 48 h posttreatment (Figs. 4A and B) . This similar effect of 1% atropine on the human and rat eye, in addition to previous reports showing similarities in structural and functional properties between the human and rat eye (Dabisch et al., 2007a; Smith et al., 1980) , may be an indication of the strong relevance of the results of this study in ocular treatment following human exposure to nerve agents.
The lowest atropine dose tested (0.1%), which induced a relatively short-term mydriasis in naïve, nonexposed eyes, was effective in counteracting both of these impairing effects without any long-term side effects seen at a higher 1% dose (Figs. 4A and 10A) . The lower 0.1% dose was also sufficient against sarininduced ocular damage (Figs. 7 and 11) .
Homatropine is a long-term anti-cholinergic drug less potent than atropine, which at 2% showed a short-term mydriasis in nonexposed eyes similar to that seen following 0.1% atropine. Homatropine 2% was beneficial in counteracting the ocular insult following VX (Figs. 6 and 10) and sarin (Figs. 8 and 11 ). The beneficial effects of 2% homatropine against sarin-induced ocular insult were restricted by a narrow therapeutic window: 1% homatropine showing a very weak beneficial response while 5% showed untoward mydriasis ( Figure 8A ).
Since in some scenarios medical treatment will be available on site, casualties of OP exposure will be treated with autoinjectors consisting atropine and an oxime (eg, TA autoinjectors content: 80 mg TMB-4 and 2 mg atropine) (Bentur et al., 2006; Kozer et al., 2005) . The efficacy of this treatment was previously evaluated against the sarin-induced ocular insult (Gore et al., 2015) . In this study, we showed that one TA treatment was not sufficient in ameliorating the ocular VX-insult and an additional treatment was required in order to obtain a relatively stable response (Figure 9 ). In an attempt to avoid possible systemic side effects of atropine (Hurst et al., 2007 ) TA treatment Figure 8 . Dose-and time-dependent effects on pupil response of topical sarin 1 mg exposure treated with homatropine. Eyes were treated with various doses of homatropine and pupil width (relative to pre-exposure baseline of the same animal) (A) and light reflex (percent of pupil width change relative to prereflex level) (B) were monitored for up to 2 weeks (n ¼ 12/group), *p < .001 (ANOVA) between groups at the same time point indicated by asterisk (pupil width), *versus groups with no asterisks at the same time point (light reflex). may be followed by topical treatment of 0.1% atropine or 2% homatropine, which showed a beneficial role in generating a stable pupil diameter (Figure 9) .
Victims from the sarin chemical warfare terrorist attacks in Matsumoto, June 1994, and Tokyo, March 1995, were treated with atropine, cyclopentolate or tropicamide (with phenylephrine) anticholinergic topical eye drops, which appeared to be useful in dilating pupils and bringing relief to ocular pain (Nohara and Segawa, 1996) . It should be emphasized that the use of cyclopentolate, following sarin exposure had previously been shown to worsen visual acuity (Moylan and Thomas, 1973) and that the use of potent anticholinergic eye drops such as atropine were advised not be used unless pain is severe, since it may produce prolonged mydriasis and cycloplegia, which may worsen visual ability (Holstege et al., 1997) . No other optional treatments were advised in these studies. In this work, it has been shown that topical tropicamide with or without oxime treatment, which was shown to be an effective treatment against sarin-induced miosis, was not beneficial in alieving the VX induced miosis. To date, atropine or homatropine eye drops are the currently used treatments in ameliorating the ocular insult following OP ocular exposure (Hurst et al., 2007) . Guidelines suggest that an individual with relatively mild effects (miosis, dyspnea, rhinorrhea) may be returned to duty within 1 to several days or even hours depending on the visual performance (Hurst et al., 2007; Sidell et al., 1997) , a task that may be impossible if potent anticholinergic treatments are used. In this work, it has been shown that 0.1% atropine (1 drop following sarin exposure and 2 drops following VX exposure) or 2% homatropine eye drops would be sufficient in alieving ocular OP induced insult. However, since individuals may react differently (depending on gender, dose of exposure and iris pigmentation) additional treatment may be needed. In this case, low concentration eye drop administration may be continued by a buddy or medical personal until ocular relief is achieved. Relief will be indicated by decrease in eye pain and relieving headaches, nausea, and vomiting due to ocular pain. In addition, pupils regain their ability to react to light and no dimness of vision or reduction in the visual field is noted. All together a successful treatment will be defined as a treatment, which will enable functional vision.
The universal treatment protocol suggested here based on the present and previous studies, includes immediate topical application of 0.1% atropine in casualties presenting ocular insult alone or if required as a continues treatment following administration of TA. This treatment is expected to shorten and attenuate the impact of the VX-and sarin-induced ocular insult and the associated impairment in visual functions. It is also expected to reduce the need of repeated anticholinergic treatments, and reduce or eliminate possible side effects.
In summary:
1. Eye drops of 0.1% atropine or 2% homatropine induce short mydriasis in case of misuse. 2. Topical 0.1% atropine or 2% homatropine eye drops ameliorated the sarin-and VX-induced ocular insult. Because of the narrow therapeutic window of homatropine, atropine 0.1% is preferable. 3. The use of topical 0.1% atropine or 2% homatropine eye drops may reduce the need of repeated anticholinergic treatments and thus should be considered as the treatment of choice in very mild casualties or against long-term ocular insult instead of the current treatment of high doses atropine or homatropine eye drops. 4. Intramuscular TA treatment will probably not be sufficient in counteracting the VX-induced miosis. 5. In case of nonsufficient ocular effect following TA treatment or in case of prolonged visual insult with no other systemic symptoms, 0.1% atropine or 2% homatropine eye drops would be advised. 6. Following initial i.m. or topical anticholinergic treatment, miosis and ocular pain should be monitored before additional topical anticholinergic eye drops treatment are used, as this additional treatment may induce side effects of mydriasis and thus visual impairment. Performance of cued water maze task was determined 15 min later under room light conditions. The parameters examined and compared between groups were escape latency (A), path length (B), and swimming speed (C). Each block is the average of 4 successive trials (n ¼ 12/group), *p < .001 (MANOVA) vs. all other groups in the same block. The main effect between blocks 1 and 2 was significant at a level of p < .001. Figure 11 . Visual function following topical sarin exposure and topical anticholinergic treatments. Both rat eyes were treated topically with saline or 0.1% atropine or 2% homatropine 20 min following 0.66% PG (control) or 1 l sarin exposure.
Performance of cued water maze task was determined 15 min later under room light conditions. The parameters examined and compared between groups were escape latency (A), path length (B), and swimming speed (C). Each block is the average of 4 successive trials (n ¼ 12/group), *p < .001 (MANOVA) versus all other groups in the same block (except for the GB: homatropine group in the first block). The main effect between blocks 1 and 2 was significant at a level of p < .001.
